Centessa Pharmaceuticals (NASDAQ:CNTA) Given New $28.00 Price Target at Guggenheim

Centessa Pharmaceuticals (NASDAQ:CNTA) had its price objective boosted by research analysts at Guggenheim from $24.00 to $28.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price objective indicates a potential upside of 69.39% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on CNTA. BMO Capital Markets boosted their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. B. Riley assumed coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Finally, Jefferies Financial Group raised their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA traded down $0.97 during trading on Friday, reaching $16.53. 299,767 shares of the stock traded hands, compared to its average volume of 402,999. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 13.29. The stock has a market capitalization of $1.87 billion, a P/E ratio of -10.75 and a beta of 1.47. Centessa Pharmaceuticals has a 52-week low of $5.58 and a 52-week high of $18.74. The company has a 50-day moving average of $15.87 and a 200-day moving average of $12.07.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Analysts forecast that Centessa Pharmaceuticals will post -1.68 EPS for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 11,742 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $15.38, for a total value of $180,591.96. Following the completion of the transaction, the insider now owns 183,266 shares in the company, valued at approximately $2,818,631.08. This represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $16.53, for a total transaction of $909,150.00. Following the sale, the chief executive officer now owns 721,924 shares in the company, valued at approximately $11,933,403.72. This trade represents a 7.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 325,031 shares of company stock valued at $5,213,043 in the last 90 days. Insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in CNTA. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC increased its stake in Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares in the last quarter. Quarry LP raised its holdings in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares during the last quarter. Sandia Investment Management LP bought a new position in shares of Centessa Pharmaceuticals in the second quarter worth approximately $90,000. Finally, Fred Alger Management LLC purchased a new stake in shares of Centessa Pharmaceuticals during the second quarter valued at approximately $99,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.